Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Friday.
A number of other equities research analysts have also recently commented on the company. Cantor Fitzgerald set a $50.00 target price on Aclaris Therapeutics and gave the stock a “buy” rating in a research note on Friday, December 15th. Zacks Investment Research cut Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. ValuEngine cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, September 12th. Finally, JMP Securities reiterated an “outperform” rating and set a $39.00 target price on shares of Aclaris Therapeutics in a research note on Friday, September 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $39.20.
Shares of Aclaris Therapeutics (NASDAQ:ACRS) opened at $25.14 on Friday. The company has a market capitalization of $736.64, a price-to-earnings ratio of -11.64 and a beta of 1.96. Aclaris Therapeutics has a 52 week low of $21.32 and a 52 week high of $33.25.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. increased its holdings in Aclaris Therapeutics by 40.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 61,765 shares of the biotechnology company’s stock worth $1,676,000 after acquiring an additional 17,804 shares during the last quarter. Cadence Capital Management LLC purchased a new stake in Aclaris Therapeutics in the 3rd quarter worth about $689,000. Franklin Resources Inc. increased its holdings in Aclaris Therapeutics by 55.4% in the 2nd quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock worth $53,030,000 after acquiring an additional 697,104 shares during the last quarter. Citadel Advisors LLC increased its holdings in Aclaris Therapeutics by 620.6% in the 3rd quarter. Citadel Advisors LLC now owns 242,016 shares of the biotechnology company’s stock worth $6,247,000 after acquiring an additional 208,429 shares during the last quarter. Finally, Rosenblum Silverman Sutton S F Inc. CA increased its holdings in Aclaris Therapeutics by 17.3% in the 2nd quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 38,400 shares of the biotechnology company’s stock worth $1,041,000 after acquiring an additional 5,650 shares during the last quarter. 92.02% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Aclaris Therapeutics (ACRS) Upgraded to Hold by BidaskClub” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.com-unik.info/2017/12/29/aclaris-therapeutics-acrs-upgraded-to-hold-by-bidaskclub.html.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
What are top analysts saying about Aclaris Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aclaris Therapeutics and related companies.